Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI137093, R01AI137093, R01AI137093)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 20 April 2022
Accepted: 11 October 2022
First Online: 27 October 2022
Competing interests
: V.E.P. has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial virus. D.M.W. has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is the principal investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. Z.Z. is expected to receive consulting fees from Pfizer for work unrelated to this manuscript.
